Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Glaukos ( (GKOS) ) just unveiled an update.
On January 13, 2026, Glaukos announced preliminary, unaudited results showing fourth-quarter 2025 net sales of about $143 million, up 36% year-on-year, driven by $86 million in U.S. glaucoma sales including $45 million from iDose TR, $33 million in international glaucoma sales and $24 million in corneal health revenue. For full-year 2025, net sales are expected to reach approximately $507 million, a 32% increase over 2024, with $299 million in U.S. glaucoma sales (including $136 million from iDose TR), $122 million in international glaucoma sales and $86 million in corneal health sales; the company ended the year with roughly $283 million in cash and no debt, reaffirmed its 2026 revenue guidance of $600 million to $620 million, and plans to report final fourth-quarter and full-year 2025 results on February 17, 2026, underscoring strong execution and momentum in its core glaucoma and corneal health franchises.
The most recent analyst rating on (GKOS) stock is a Buy with a $138.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
Glaukos’s strong sales growth and strategic product developments are significant positives. However, profitability challenges and valuation concerns weigh on the overall score. The technical indicators suggest bullish momentum, but caution is advised due to overbought signals.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company specializing in novel therapies for glaucoma, corneal disorders and retinal diseases. It pioneered Micro-Invasive Glaucoma Surgery (MIGS), launched its first MIGS device in 2012, began commercial launch activities in 2024 for iDose TR, a long-duration intracameral glaucoma therapy, and markets the only FDA-approved corneal cross-linking therapy using a proprietary bio-activated pharmaceutical for keratoconus, while advancing a broad pipeline of dropless platform technologies for chronic eye diseases.
Average Trading Volume: 1,073,567
Technical Sentiment Signal: Buy
Current Market Cap: $6.49B
Find detailed analytics on GKOS stock on TipRanks’ Stock Analysis page.